X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs BIOCON - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA BIOCON ASTRAZENECA PHARMA/
BIOCON
 
P/E (TTM) x 89.2 18.3 486.8% View Chart
P/BV x 19.7 2.9 680.0% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 ASTRAZENECA PHARMA   BIOCON
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
BIOCON
Mar-18
ASTRAZENECA PHARMA/
BIOCON
5-Yr Chart
Click to enlarge
High Rs1,2781,188 107.6%   
Low Rs883305 289.4%   
Sales per share (Unadj.) Rs228.468.7 332.3%  
Earnings per share (Unadj.) Rs10.47.6 137.2%  
Cash flow per share (Unadj.) Rs16.314.0 116.4%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.1 0.0%  
Book value per share (Unadj.) Rs98.886.3 114.4%  
Shares outstanding (eoy) m25.00600.00 4.2%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x4.710.9 43.5%   
Avg P/E ratio x104.298.9 105.4%  
P/CF ratio (eoy) x66.453.4 124.3%  
Price / Book Value ratio x10.98.6 126.5%  
Dividend payout %013.2 0.0%   
Avg Mkt Cap Rs m27,008447,900 6.0%   
No. of employees `0001.46.1 22.1%   
Total wages/salary Rs m1,5359,311 16.5%   
Avg. sales/employee Rs Th4,210.96,705.8 62.8%   
Avg. wages/employee Rs Th1,132.21,514.2 74.8%   
Avg. net profit/employee Rs Th191.1736.9 25.9%   
INCOME DATA
Net Sales Rs m5,71041,234 13.8%  
Other income Rs m1232,062 5.9%   
Total revenues Rs m5,83343,296 13.5%   
Gross profit Rs m4638,291 5.6%  
Depreciation Rs m1473,851 3.8%   
Interest Rs m0615 0.0%   
Profit before tax Rs m4385,887 7.4%   
Minority Interest Rs m0213 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1791,569 11.4%   
Profit after tax Rs m2594,531 5.7%  
Gross profit margin %8.120.1 40.3%  
Effective tax rate %40.826.7 153.3%   
Net profit margin %4.511.0 41.3%  
BALANCE SHEET DATA
Current assets Rs m3,20941,486 7.7%   
Current liabilities Rs m2,07021,413 9.7%   
Net working cap to sales %20.048.7 41.0%  
Current ratio x1.61.9 80.0%  
Inventory Days Days7264 113.1%  
Debtors Days Days3594 37.1%  
Net fixed assets Rs m79050,661 1.6%   
Share capital Rs m503,000 1.7%   
"Free" reserves Rs m2,41948,808 5.0%   
Net worth Rs m2,46951,808 4.8%   
Long term debt Rs m017,898 0.0%   
Total assets Rs m4,60599,897 4.6%  
Interest coverage xNM10.6-  
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x1.20.4 300.4%   
Return on assets %5.65.2 109.2%  
Return on equity %10.58.7 120.0%  
Return on capital %17.79.6 184.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m30012,058 2.5%   
Fx outflow Rs m2,0157,348 27.4%   
Net fx Rs m-1,7154,710 -36.4%   
CASH FLOW
From Operations Rs m886,621 1.3%  
From Investments Rs m-94-6,840 1.4%  
From Financial Activity Rs mNA-2,397 0.0%  
Net Cashflow Rs m-6-2,612 0.2%  

Share Holding

Indian Promoters % 0.0 40.4 -  
Foreign collaborators % 75.0 20.6 364.1%  
Indian inst/Mut Fund % 0.3 8.4 3.6%  
FIIs % 15.7 10.7 146.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 19.9 45.7%  
Shareholders   12,856 109,995 11.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   FDC LTD.  UNICHEM LAB  DR. REDDYS LAB  ELDER PHARMA  ALEMBIC LTD  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 71 Points Lower; Metal and Energy Stocks Witness Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their volatile trading day marginally lower.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)

Jan 28, 2019 | Updated on Jan 28, 2019

For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)

Jun 11, 2019

One chart that predicted the NBFC crisis back in 2016.

Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)

Jun 12, 2019

This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.

Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)

Jun 14, 2019

Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.

7 Bluechips to Profit from Tech Disruption(Profit Hunter)

Jun 17, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jun 24, 2019 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS